
In the largely rural Central San Joaquin Valley, a reporter tracking efforts to expand access to health care in the wake of Obamacare finds that "many of the most effective outreach tools at play involve very little technology."
In the largely rural Central San Joaquin Valley, a reporter tracking efforts to expand access to health care in the wake of Obamacare finds that "many of the most effective outreach tools at play involve very little technology."
Will a diagnosis of “prediabetes” motivate meaningful lifestyle changes among patients, or simply lead patients and providers to use medications rather than refocus on aggressive lifestyle changes?
The Los Angeles Department of Health Services will start approving hepatitis C drugs for active IV drug users. Until now, the department had withheld approval for anyone who had not been drug-free for at least six months.
In California’s Central Valley and rural north, more than a dozen hospitals have closed since the early 2000s. The closures often limit care options and inflict economic misery — some communities never recover.
Physicians are often terrible at heeding their own advice. "Among a trio of lung specialists I once knew, only one was not a chain smoker himself," writes Dr. Monya De. How does this happen?
In a recent Reuters series, a team of reporters exposed what we still don't know about superbugs and highlighted a huge hole in that knowledge: the inaccuracy of death certificates.
California's psychiatric hospitals can be highly dangerous places, both for patients and staff. Lost work days and overtime pay are huge. But reporters looking to track down reliable data on assaults face an uphill climb.
Donald Trump and Hillary Clinton are merely the latest in a long line of American politicians who have cast aspersions on the Canadian health care system. Here's what they don't get.
In the first presidential debate between Hillary Clinton and Donald Trump, health care scarcely came up. Yet it remains among the most urgent issues facing Americans. Insurance premiums continue their upward march, out-of-pocket costs are soaring and insurance exchanges keep shrinking.
A program that creates market incentives to encourage drug makers to target rare pediatric diseases seemed like good policy at first. But evidence of the program's effectiveness is missing.